The leading global voice
We play a major role in bringing the CV community together to drive transformational change.
Together we are stronger
By 2025, our aim is to reduce premature deaths from CVD by at least 25%.
Join the fight
Become a WHF member and help us to build global commitment to address cardiovascular health at the policy level.
We convene and connect our members
To share science, best practice and resources, acting as a global thought leader and catalyst for positive change.
Celebrate World Heart Day
The biggest global awareness-raising campaign for CVD.
Attend the Congress
Join world leaders in heart health, share ideas, network with specialists.
Advocating for heart health
We lead the global advocacy effort for action to prevent, control and reduce the global burden of CVD.
All our programmes and partnerships are aimed at creating awareness of CVD as a priority issue across the globe.
Find out more about our and our members' work around the world.
Explore everything from toolkits, videos and infographics, to policy reports, factsheets and more.
Science and Research
“These are incredibly important findings with potential for significant global impact,” said Dr. Salim Yusuf, principal investigator and executive director of PHRI. “If just 10 percent of the world’s population at intermediate risk of CVD [cardiovascular disease] is impacted, we’re talking about 20 to 30 million people who could be helped by these drugs.”
Three studies on the methods have been published this week in the New England Journal of Medicine. Under the name of HOPE-3, or Heart Outcomes Prevention Evaluation-3, the studies involved 228 centres looking at the effects of the three treatments in people at intermediate risk of, but without, clinical heart disease.
The three methods examined included two forms of therapy: Statins, a group of cholesterol-lowering drugs, and antihypertensives, a class of drugs used to treat high blood pressure. In addition, a combination of statins and antihypertensives was reviewed.
Statins proved to significantly and safely reduce CVD events by 25 per cent in patients at intermediate risk without CVD. Antihypertensives did not reduce major CVD events overall in the population studied, but did reduce such events in the group of people with hypertension, but not in those without hypertension. When combined, statins and antihypertensives reduced CVD events by 30 per cent—with a 40% benefit in those with hypertension, suggesting that patients with hypertension should not only lower their BP but also consider taking a statin.
HOPE-3’s findings will have a major influence on primary care in developed nations, where statins and antihypertensives are inexpensive, Yusuf added. While still relatively inexpensive in developing nations, the drugs are less affordable in relation to income. Still, Yusuf said the study’s results hold promise everywhere as the price of these drugs start to come down.
“These simple methods can be used practically everywhere in the world, and the drugs will become even cheaper as more and more systems and people adopt these therapies,” he said.
The HOPE-3 research reports were led by Yusuf and Dr. Eva Lonn, both professors of medicine of McMaster’s Michael G. DeGroote School of Medicine, and Jackie Bosch, an associate professor of the university’s School of Rehabilitation Science.
Articles on the research have also appeared widely around the world both online and in print including the Japan Times, Stat News, Reuters and World Tech Today.
Global Alliance for Chronic Diseases publishes Hypertension Programme Report
WHF Cholesterol Roadmap presented at the Latin American Cholesterol Summit in Mexico
Symposium on 'Fixed-dose combinations for CVD and hypertension' at the London School of Hygiene & Tropical Medicine